Literature DB >> 8906515

Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of slat sensitivity and resistance.

C Yagil1, G Katni, S Rubattu, C Stolpe, R Kreutz, K Lindpaintner, D Ganten, D Ben-Ishay, Y Yagil.   

Abstract

OBJECTIVES: Variations in the blood pressure response to salt-loading, the lack of quality control measures, and the need to prepare the strains for genetic studies led to renewed secondary inbreeding of the original colony of Sabra hypertension prone (SBH) and resistant (SBN) rats in order to regain genotypic and phenotypic homogeneity of the substrains.
METHODS: Animals from the original breeding colony were selectively inbred for basal normotension and for susceptibility or resistance to the development of hypertension following salt-loading with deoxycorticosterone acetate (DOCA)-salt. Efficacy of inbreeding was tested by genome screening with 416 microsatellite primer sets. Phenotyping was based on measurements of systolic blood pressure by the tail-cuff methodology in awake, undisturbed animals maintained on standard diet and after salt-loading with DOCA-salt. Telemetric measurements of blood pressure were performed in a small number of animals to validate tail-cuff measurements.
RESULTS: Animals from the new colony were designated SBH/y and SBN/y to differentiate from the original colony. Fourteen generations have been inbred over the past 4 years. Of the 402 microsatellites that amplified, 183 (45.5%) were polymorphic between the two substrains, and not a single locus was found to be heterozygous in either substrain. Phenotypic characteristics are provided for SBH/ y and SBN/y rats with respect to tail-cuff systolic blood pressure. The values obtained, which were validated by telemetry, demonstrate classical features of salt sensitivity or resistance, respectively.
CONCLUSIONS: The genetic homogeneity found in SBH/y and SBN/y, the phenotype demonstrating salt-sensitivity or salt-resistance in terms of development of hypertension, and the relatively high frequency of informative genetic markers identify this Sabra rat model as highly suited for studies concerning the molecular genetics of gene-environment interactions affecting blood pressure regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906515     DOI: 10.1097/00004872-199610000-00004

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Authors:  Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

2.  Three interacting genomic loci incorporating two novel mutations underlie the evolution of diet-induced diabetes.

Authors:  Yoram Yagil; Barak Markus; Refael Kohen; Chana Yagil
Journal:  Mol Med       Date:  2016-07-26       Impact factor: 6.354

Review 3.  Dietary sodium and cardiovascular outcomes: a rational approach.

Authors:  S Brian Penner; Norm R C Campbell; Arun Chockalingam; Kelly Zarnke; Bruce Van Vliet
Journal:  Can J Cardiol       Date:  2007-05-15       Impact factor: 5.223

4.  Mesenchymal Stem Cell-Derived Extracellular Vesicles as Proposed Therapy in a Rat Model of Cerebral Small Vessel Disease.

Authors:  Reut Guy; Shay Herman; Hadar Benyamini; Tali Ben-Zur; Hila Kobo; Metsada Pasmanik-Chor; Dafna Yaacobi; Eric Barel; Chana Yagil; Yoram Yagil; Daniel Offen
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

5.  A novel mutation in the NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (Ndufa4) gene links mitochondrial dysfunction to the development of diabetes in a rodent model.

Authors:  Chana Yagil; Ronen Varadi-Levi; Yoram Yagil
Journal:  Dis Model Mech       Date:  2018-11-20       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.